Streetbeat News

Stock Prices

MSCI

Over the past 10 years, MSCI (NYSE:MSCI) has significantly outperformed the market, yielding an average annual return of 28.89%. A $100 investment in MSCI a decade ago would now be worth $1,269.89. MSCI's market capitalization currently stands at $43.90 billion.

Portfolio Pulse from Benzinga Insights

January 05, 2024 | 4:00 pm

ELAN

Elanco Animal Health's stock (ELAN) is trading higher following an upgrade from Stifel, moving from a Hold to a Buy rating, with an increased price target from $13 to $20.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:56 pm

AUPH

Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH) reported preliminary Q4 and full year 2023 financial results, with revenues exceeding estimates and a 31% year-over-year growth. The company expects to become cash flow positive in the second half of 2024 and has submitted an IND application to the FDA for AUR200. Shares are up 4.39% on heavy trading volume, with 11.4% of shares sold short.

Portfolio Pulse from Erica Kollmann

January 05, 2024 | 3:56 pm

HGEN

Humanigen (OTC:HGEN) has filed for bankruptcy following the FDA's rejection of its COVID-19 drug, lenzilumab. The company reported $44.1 million in unsecured debts against assets of $521,000. The FDA's decision, legal challenges, and studies questioning the drug's efficacy have led to a financial crisis for Humanigen, resulting in its delisting from Nasdaq in October 2023. The stock has lost almost all value from its previous $20 trading range.

Portfolio Pulse from Vandana Singh

January 05, 2024 | 3:55 pm

SANA

Sana Biotechnology, Inc. (NASDAQ:SANA) shares rose after the FDA cleared its IND application for SC262, a study for patients with relapsed or refractory B-cell malignancies. This clearance follows a previous FDA clearance for SC291 for lupus nephritis and related conditions. The company anticipates presenting data from multiple studies, including SC262, later in the year. SANA's stock price increased by 2.24% to $5.01.

Portfolio Pulse from Nabaparna Bhattacharya

January 05, 2024 | 3:54 pm

DT

Jefferies analyst Brent Thill has upgraded Dynatrace (NYSE:DT) from Hold to Buy and increased the price target from $50 to $70.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:52 pm

BAC

JPM

JPMorgan Chase & Co (JPM) stock hit a new 52-week high of $173.35, reflecting a 25% increase over the past year, largely gained in the last two months. Positive trends and a rising OBV indicator suggest further potential growth. Bank of America Corp. (BAC) Securities sees U.S. banking stocks, especially mega-cap banks, as undervalued with a 50% P/E discount to the S&P 500. Analysts are bullish on JPM with price targets of $188 and $212. JPMorgan's market share growth and operational efficiencies are expected to continue driving its stock value up.

Portfolio Pulse from Surbhi Jain

January 05, 2024 | 3:49 pm

MPW

Medical Properties Trust (MPW) shares dropped following the announcement of its intent to recover uncollected rents and outstanding loan obligations from Steward Health Care System. Additionally, Keybanc downgraded MPW from Overweight to Sector Weight.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 3:46 pm

AAPL

GOOGL

META

MSFT

NVDA

QQQ

SPY

TSLA

The Market Clubhouse Morning Memo provides daily trading levels for SPY, QQQ, AAPL, MSFT, TSLA, GOOGL, META, and NVDA based on a proprietary formula considering price, volume, and options flow. The memo outlines potential bullish and bearish price targets for each asset and advises traders to monitor these stocks closely for breakouts or reversals. The release of the Non-Farm Payrolls report is expected to significantly influence market sentiment and volatility. The memo is part of the Market Clubhouse membership, which offers daily market analysis, a watch list, and real-time trading mentorship by a professional trader known as RIPS.

Portfolio Pulse from RIPS

January 05, 2024 | 3:46 pm

ADSK

Hedge funds and asset managers, including Amundi, D.E. Shaw, and Woodline Partners LP, have increased their holdings in Autodesk Inc. (NASDAQ:ADSK), with D.E. Shaw notably raising their stake by 73.96%. Autodesk reported a 10% YoY increase in Q3 FY24 revenue and raised FY24 guidance. The company is recognized for its 3D design software and operates with high margins and ROE. Management aligns with shareholder interests through share repurchases and performance-based compensation. Autodesk's financial health is solid with a strong cash position and manageable debt. However, a reverse discounted cash flow analysis suggests the current valuation may be high, with a potential 35% downside in share price.

Portfolio Pulse from Quiver Quantitative

January 05, 2024 | 3:41 pm